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A análise fitoquímica do extrato acetato de etila da casca do caule de Clusia pernambucensis 
G. Mariz, Clusiaceae, uma espécie do Cerrado brasileiro, conduziu ao isolamento e caracterização 
completa de uma nova xantona, 1,7-dihidróxi-2-(3-metil-2-butenil)-6’,6’-dimetilpirano(2’,3’:3,4)
xantona, denominada clusiaxantona. Quatro tocotrienóis ainda não relatados nesta espécie também 
foram isolados. Um derivado foi obtido a partir da clusiaxantona, 1-hidróxi,7-metóxi-2-(3-metil-
2-butenil)-6’,6’-dimetilpirano(2’,3’:3,4)xantona (7-O-metil-clusiaxantona), e um segundo derivado 
foi obtido a partir do ácido Z-δ-tocotrienolóico. As estruturas foram estabelecidas com base em 
dados de ressonância magnética nuclear de 1H e 13C (NMR 1D e 2D), espectrometria de massa com 
ionização por electrospray de alta resolução (HRESIMS) e espectroscopia no infravermelho. No 
controle da infecção de macrófagos com amastigotas de Leishmania (Leishmania) amazonensis, 
os compostos ativos foram clusiaxantona e seu derivado (CI50 = 66,9 e 57,4 µM, respectivamente). 
A citotoxicidade dos compostos foi determinada em macrófagos peritoneais de camundongos 
BALB/c.
Phytochemical analysis of the ethyl acetate extract from the stem bark of Clusia pernambucensis 
G. Mariz, Clusiaceae, a Brazilian Cerrado species, led to the isolation and full characterization of 
a new xanthone, 1,7-dihydroxy-2-(3-methyl-2-butenyl)-6’,6’-dimethylpyrano(2’,3’:3,4)xanthone, 
namely clusiaxanthone. Four previously unreported tocotrienols from this species were also 
isolated. A derivative was obtained from clusiaxanthone, 1-hydroxy,7-methoxy-2-(3-methyl-
2-butenyl)-6’,6’-dimethylpyrano(2’,3’:3,4)xanthone (7-O-methylclusiaxanthone), and an additional 
derivative was obtained from Z-δ-tocotrienoloic acid. The structures of these compounds were 
established based on data from 1H and 13C nuclear magnetic resonance (1D and 2D NMR), high 
resolution electrospray ionization mass spectrometry (HRESIMS) and infrared spectroscopy. 
The clusiaxanthone and its derivative were able to control macrophage infection by Leishmania 
(Leishmania) amazonensis amastigotes (IC50 = 66.9 and 57.4 µM, respectively). The cytotoxicity 
of the compounds was assessed in BALB/c mouse peritoneal macrophages.
Keywords: Clusia pernambucensis, Clusiaceae, xanthone, tocotrienol series, Leishmania 
(Leishmania) amazonensis
Silva et al. 1315Vol. 24, No. 8, 2013
Introduction
Cutaneous leishmaniasis is a worldwide endemic 
disease that causes skin lesions usually persisting for several 
months or years.1 Patients also suffer because of the toxicity 
induced by prolonged use of antileishmanial drugs. The 
clinical symptoms of leishmaniasis are determined by the 
involved species of Leishmania, the parasite virulence and 
host immune response.2 On account of the limited treatment 
options,3 new therapeutic solutions have been proposed, 
such as the use of miltefosine and paromomycin4 for the 
past twenty years.
Despite these efforts, the need for new drugs remains. 
However, progress in the development of new treatments 
has been slow.2,5-7 As previously reported, the screening 
for compounds from natural product libraries is a key 
strategy because many plants contain chemical compounds 
with powerful leishmanicidal activity.8,9 In addition, 
approximately 80% of the population in the Americas use 
plants to treat various diseases,10 including leishmaniasis.11,12
Benzophenones, triterpenes and several flavonoids have 
been isolated from Clusia pernambucensis, C. columnaris, 
C. grandiflora and C. spirictu-sanctensis.13,14 These 
compounds have presented anti-inflammatory, antifungal, 
antibacterial,15 anti-HIV,16 antioxidant and antitumor 
activities.17-19 Peraza-Sanchez et al.20 demonstrated the 
activity of the methanol extract of C. flava leaves, popularly 
used for treating wounds and syphilis, in promastigotes 
of Leishmania major. A Peru based research team 
supported the use of traditional medicine for the treatment 
of cutaneous leishmaniasis.11 The group observed the 
activity of C. amazonica extracts in L. amazonensis axenic 
amastigotes.11
In  th i s  s tudy,  we  eva lua ted  the  poten t ia l 
antileishmanial effects of compounds and derivatives 
from Clusia pernambucensis G. Mariz, Clusiaceae against 
Leishmania (Leishmania) amazonensis, a parasite species 
that causes cutaneous leishmaniasis.
Results and Discussion
The fractionation of the ethyl acetate extract from the 
stem bark of Clusia pernambucensis led to the isolation of a 
previously unreported compound, clusiaxanthone (1), and six 
known compounds (2-7), δ-tocotrienol (2),21 δ-tocotrienolic 
alcohol (3),22 Z-δ-tocotrienoloic acid (4) and δ-tocotrienol 
methyl ester (5),23 betulinic acid (6),24,25 and β-sitosterol (7)26 
(Figure 1). Compounds 2 and 5 were isolated from a natural 
source for the first time. For Z-δ-tocotrienoloic acid (4), the 
chemical shift of the methyl 12a’ carbon (d 12.21 ppm) 
under the protective effect of the γ-methylenic carbon 10’ 
(d 27.78 ppm) contributed to the stereochemical identification 
of the carboxyl group. The structures of compounds 2-7 were 
determined by comparing the experimental data from the 
1H and 13C nuclear magnetic resonance (NMR) spectra and 
high resolution electrospray ionization mass spectrometric 
(HRESIMS) analyses with previously reported data. This 
was the first time compounds 2 to 5 were isolated from 
C. pernambucensis. 
The methylation of clusiaxanthone and Z-δ-tocotrienolic 
acid resulted in the derivatives 1a, 1-hydroxy,7-methoxy-
2-(3-methyl-2-butenyl)-6’,6’-dimethylpyrano(2’,3’:3,4)




Clusiaxanthone (1) was isolated as a yellow solid with 
[α]D -57.4 (MeOH, c 0.11). The molecular formula for 
clusiaxanthone was determined as C23H22O5 based on the 
quasi-molecular ion at m/z 379.1540 [M + H]+ (1 ppm 
error) in the HRESIMS spectrum. The vibrational bands 
at 3325 and 1647 cm-1 in the IR spectrum were consistent 
with hydroxyl and carbonyl groups, respectively.
The 1H NMR spectrum of clusiaxanthone (500 MHz, 
C5D5N) showed signals at dH 1.74 (s, 3H-4’), 1.96 (s, 
3H-5’), 3.62 (d, J 7.5 Hz, 2H-1’) and 5.49 (t’, J 7.5 Hz, 
H-2), and correlations with the carbon signals (1JCH) at 
dC 18.5 (CH3-5’), 26.2 (CH3-4’), 22.3 (CH2-1’) and 123.4 
(CH-2’) in the HSQC spectrum, respectively, used to 
characterize the presence of a prenyl moiety. The presence 
of a 2,2-dimethyl-3,4-dehydropyran was also identified by 
the signals at dH 1.49 (s, 6H-3H4”/3H5’’), 5.65 (d, H-2”, 
10.0 Hz) and 6.97 (d, H-1’’, 10.0 Hz), which showed 
correlations (1JCH) with the signals corresponding to carbons 
C-4”/C-5” (d 28.6), C-2" (d 116.5) and C-1" (d 128.2) in 
the HSQC spectrum, respectively. The signal at dH 13.86 
(s) in the 1H NMR spectrum suggested the presence of a 
chelatogenic hydroxyl group (HO-1) (Table 1).
The 13C NMR spectrum (125 MHz, C5D5N) of 
compound 1, which was supported by the data from the 
13C DEPT (distortionless enhancement by polarization) 
Figure 1. Structures of the isolated compounds 1-5 and semi-synthetic 
derivatives 1a and 4a.
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135 analysis, revealed 23 signals corresponding to twelve 
non-hydrogenated, six methine (all sp2), one methylene 
(sp3) and four methyl carbon atoms. Therefore, the 
expanded molecular formula C23H22O7 was determined 
for compound 1 based on these data, and this formula is 
consistent with the chemical formula of C23H22O5, which 
was determined by HRESIMS, with the presence of two 
ether functions.
For compound 1, a signal at dC 181.9 was assigned 
to a carbonyl carbon (C-9), three signals were associated 
with mono-hydrogenated aromatic carbons at dC 109.2 
(C-8), 119.8 (C-5) and 125.7 (C-6), and eight signals were 
correlated with non-hydrogenated aromatic carbons at 
d 104.1 (C-9a), 104.7 (C-4a), 107.9 (C-2), 121.8 (C-8a), 
155.2 (C-1), 156.6 (C-4a), 156.0 (C-7) and 158.7 (C-3). 
The last four carbons represent oxygenated carbons. It was 
also possible to observe the presence of two olefin carbons 
at dC 123.4 (C-2’) and 131.8 (C-3’) associated with a tri-
substituted double bond in the prenyl side chain, and two 
additional carbons at dC 116.5 (C-1”) and 128.2 (C-2”) of 
the pyran substituent. The location of the carbons in the 
xanthone skeleton and all the unequivocal chemical shift 
assignments were based on the heteronuclear long-range 
coupling (2JCH and 3JCH) between the hydrogen and carbon 
atoms as determined by the 2D HMBC spectrum. The 
location of the prenyl moiety at C-2 was indicated by the 
HMBC correlations between the methylene protons 2H-1’ 
(dH 3.62) with both C-2’ (dC 123.4, 2JCH) and C-2 (dC 107.9, 
2JCH) carbons. The location of the prenyl moiety was also 
confirmed by correlations with both the C-1 (dC 155.2, 
Table 1. 1H and 13C NMR data of compounds 1 and 1a, including the results of the HSQC and HMBC analysesa
1, C5D5N 1a, CDCl3 + CD3OD
HSQC HMBC HSQC
dC / ppm dH / ppm 2JCH / Hz 3JCH / Hz dC / ppm dH / ppm
1 155.2 - 2H-1’ 156.0 -
2 107.9 - 2H-1’ H-2’ 107.5 -
3 158.7 - H-1”; 2H-1’ 158.5 -
4 104.9 - H-1” H-2” 104.8 -
4a 156.6 - H-1” 157.2 -
5 119.8 7.53 (d, 9.0) 119.7 7.23 (d, 3.0)
6 125.7 7.58 (dd, 9.0, 3.0) H-8 129.9 7.19 (d, 9.0)
7 156.0 - H-6; H-8 H-5 165.2 -
8 109.2 8.04 (d, 3.0) 110.7 7.10 (dd. 9.0, 3.0)
8a 121.8 - H-8 H-5 122.2 -
9 181.9 - H-8 183.0 -
9a 104.1 - 104.0 -
10a 150.5 - H-5 H-6; H-8 148.6 -
1’ 22.3 3.62 (d, 7.5) 22.2 3.43 (d, 7.4)
2’ 123.4 5.49 (t, 7.5) 2H-1’ 3H-4’; 3H-5’ 123.7 5.23 (t, 7.4)
3’ 131.8 - H-2’; 3H-4’/3H-5’ 2H-1’ 131.2 -
4’ 26.2 1.74 (brs) H-2’ 26.1 1.65 (brs)
5’ 18.5 1.96 (brs) H-2’ 18.3 1.86 (brs)
1” 116.5 6.97 (d, 10.0) H-2” 117.0 6.69 (d, 10.0)
2” 128.2 5.65 (d, 10.0) H-1” 3H-4”/3H-5” 127.8 5.59 (d, 10.0)
3” 78.8 - 3H-4”; 3H-5” H-1” 78.0 -
4” 28.6 1.49 (s) H-2”; 3H-5” 28.7 1.48 (s)
5” 28.6 1.49 (s) H-2”; 3H-4” 28.7 1.48 (s)
MeO - - - - 49.2 3.31 (s)
HO-1 - 13.86 (s)
aThe number of hydrogens bound to carbon atoms was determined by the comparative analysis of 1H and DEPT 13C NMR spectra. The chemical shifts and 
coupling constants (J) were obtained from the 1D 1H NMR spectrum. A 1H-1H-COSY experiment was also used to make the molecular assignments.
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3JCH) and C-3 (dC 158.7, 3JCH) carbons. The doublet at d 6.97 
(H-1'') showed an HMBC cross-peak to the aromatic C-4 
(dC 104.9, 2JCH), C-4a (dC 156.6, 3JCH) and C-3 (dC  158.7, 
3JCH) carbons, thus establishing the connectivity of C-1” 
with C-4. Other similar interactions are summarized in 
Table 1.
The methylation of compound 1 with an ethereal 
solution of diazomethane yielded the mono methyl ether 
1a and confirmed the presence of a hydroxyl group at 
C-7, which formed the methyl ether 7-O-Me derivative 
only. This was determined by its corresponding signal at 
dC 165.2 (Table 1). A singlet at dH 13.86 (vide supra) in the 
1H NMR spectrum of 1 (Table 1) indicated the presence of 
another hydroxyl group at C-1 that chelated the carbonyl 
carbon at C-9 and interfered with the methylation by 
diazomethane. Derivative 1a had a molecular formula 
of C24H25O5 determined by the protonated peak at m/z 
393.1699 ([M + H]+ calculated m/z 393.1702) in the 
HRESIMS spectrum.
Therefore, the structure of the new xanthone isolated from 
Clusia pernambucensis was determined as 1,7-hydroxy-
2-(3-methyl-2-butenyl)-6’,6’-dimethylpyrano(2’,3’:3,4)
xanthone. This compound was named clusiaxanthone (1). 
Unlike other reported related xanthones bearing two 
hydroxyl groups in the aromatic ring, this compound has 
one OH group less, similar to that identified in Garcinia 
nigrolineata.27-30
The basic core of this chemical class is a tricycle with 
a symmetrical skeleton. Ring A is formed from the acetate 
pathway, involving 1-4 carbon atoms, whereas ring B is 
composed of the 5-8 carbon atoms and is derived from the 
shikimic acid pathway.31
The EtOAc extract  f rom the s tem bark of 
C. pernambucensis exhibited an IC50 = 65.0 µg mL-1 against 
L. (L.) amazonensis promastigotes. The antileishmanial 
activity of compounds 1-6 in peritoneal macrophages 
infected with amastigotes was also determined and 
indicated that clusiaxanthone (1) displayed the most 
significant antileishmanial activity with an IC50 = 66.9 µM 
(Table 2). The antileishmanial activity of derivative 1a was 
similar to that of 1 with an IC50 = 57.4 µM.
Azebaze et al.32 showed that the activity of synthetic 
xanthones against axenic L. amazonensis amastigotes was 
increased in the presence of prenyl groups at positions 
2 and 4, similar to the activity of the 2-substituted xanthone 
observed in this study. Hydroxylated and methoxylated 
xanthones (with structures similar to compound 1a), 
which were isolated from Andrographis paniculata 
(Acanthaceae), showed activity against L. infantum 
amastigotes inside peritoneal macrophages.33 Lipophilic 
groups play an important role in facilitating the compound 
internalization by macrophages, thereby increasing its 
availability.34,35
According to the literature, the hydroxy-substituted 
xanthone nucleus shows potential for the development 
of active derivatives against Leishmania sp., which was 
observed for the 3,6-bis-ω-diethylaminoalkoxyxanthones 
tested in L. mexicana.36 The results of this study confirm 
the data obtained in our study.
Monzote et al.37 suggested that in Leishmania sp. 
amastigotes, mitochondrial complex III can be a target for 
compounds, such as tocotrienols, that contain chromanol 
groups. Among the tocotrienols studied here, only 
Z-δ-tocotrienoloic acid (4) showed an IC50 = 181.0 µM 
against L. (L.) amazonensis amastigotes. The derivative 
compound 4a did not show increased antileishmanial 
activity. Therefore, it is possible that the presence of 
the carboxylic group is beneficial to the antileishmanial 
activity because the change in substituent groups at C12’ in 
compounds 2, 3 and 5 failed to improve the antileishmanial 
activity of tocotrienol. 
Conclusions
We isolated and extensively characterized one 
unreported xanthone (1) and a series of four known 
tocotrienols, δ-tocotrienol (2), δ-tocotrienolic alcohol 
(3), Z-δ-tocotrienoloic acid (4) and δ-tocotrienol 
methyl ester (5), which were previously undescribed in 
C. pernambucensis. Compounds 2 and 5 were isolated 
from natural sources for the first time, and two compounds, 
betulinic acid (6) and β-sitosterol (7), are ubiquitous in 
plants. Clusiaxanthone (1) showed moderate activity 
against Leishmania (Leishmania) amazonensis. 
Table 2. Compound activities against L. (L.) amazonensis amastigotes 








Clusiaxanthone (1) 66.9 ± 6.1 45.5 ± 7.7
Compound 1a 57.4 ± 4.1 83.2 ± 8.4
δ-Tocotrienol (2) > 200.0 > 400.0
δ-Tocotrienolic alcohol (3) > 200.0 400.0
Z-δ-Tocotrienoloic acid (4) 181.0 ± 8.0 > 400.0
Compound 4a > 200.0 > 400.0
δ-Tocotrienol-methyl-ester (5) > 200.0 177.0 ± 16.1
Betulinic acid (6) > 200.0 > 400.0
Amphotericin B 0.2 ± 0.1 -
Meglumine antimoniate 25.0 ± 2.2 -
Miltefosine 1.3 ± 0.5 -
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Chemical studies to identify derivatives and analogs 
with lower cytotoxicity and improved antileishmanial 
activity are desirable. These compounds can be evaluated 
using an amastigote intramacrophage system. This 
system is advantageous since it takes into account the 
pharmacokinetic barriers that all compounds must 
overcome to reach the target parasite.38,39
Our laboratory is focused on the development of 
antileishmanial candidates and is currently developing new 




Optical rotation data were collected on a DIP-370 
polarimeter. For infrared analysis, the samples were embedded 
in KBr pellets under 10,000 kgf, and the experiment was 
performed with an infrared spectrophotometer (Perkin-
Elmer RX-1). Fractionation was performed by column 
chromatography (7 × 100 cm) on silica gel (0.04-0.063 mm 
or 230-400 mesh). Thin layer chromatography (TLC) was 
performed in silica gel plates (60 F254 aluminum, Merck).
1H and 13C NMR spectra were recorded at room 
temperature on a Bruker Avance DRX 500 (500.13 and 
125.77 MHz) spectrometer using an inverse detection 
probe. The chemical shifts are expressed in parts per million 
(ppm) relative to tetramethylsilane (TMS), and the coupling 
constants (J values) are shown in hertz (Hz).
HRESIMS spectra were recorded on Bruker 
UltrOTOF and MicrOTOF spectrometers. Electrospray 
ionization was performed using a time of flight analyzer 
(ESI-TOF-MS) in both the positive and negative modes.
Analytical high-performance liquid chromatography 
(HPLC) of the samples was performed on a Waters model 1525 
coupled to a UV photodiode array detector (190-800 nm), 
series 2996, thermostatic oven and Phenomenex silica 
column (4.6 × 250 mm, 5 µm). The mobile phase consisted 
of hexane-ethyl acetate pre-filtered through 0.45 µm nylon 
membranes, vacuum degassed and sonicated for 15 min. 
Reversed phase-HPLC was performed on a Shimadzu 
SL6Vp equipment coupled to a UV photodiode array 
detector (190-800 nm) equipped with a degasser. A Shimadzu 
octadecylsilane column (4.6 × 250 mm, 5 µm) with an 
injection volume of 20 µL (2 mg mL-1) and flow rate of 
1 mL min-1 was used in the analytical mode. The separation 
was achieved on a Shimadzu preparative octadecylsilane 
(20 × 250 mm, 10 µm) column with an injection volume 
of 1 mL (20 mg mL-1) and a flow rate of 9 mL min-1. The 
compound detection was monitored at 254 nm.
Plant material
The stem bark of Clusia pernambucensis G. Mariz, 
Clusiaceae, was collected from the gallery forest of the 
Cerrado biome, Santo Antônio do Descoberto, Goiás State, at 
an altitude of 1055 metres; south latitude 15º48’35.0”; south 
longitude 48º20’12.0”. The identification of the plant was 
confirmed by Professor Dr. José Elias de Paula, and a voucher 
specimen was deposited in the Herbarium of the University 
of Brasília under the accession number (UB) 3771.
Extraction and isolation
C. pernambucensis extract (22 g) was obtained by 
macerating 197.11 g of C. pernambucensis stem bark with 
ethyl acetate. From this extract, 14.15 g were fractionated 
into 312 fractions of 100 mL by column chromatography 
with a cyclohexane-EtOAc polarity gradient (100:0; 
99:1; 98:2; 97:3; 95:5; 93:7; 90:10; 85:15; 80:20; 75:25; 
70:30; 60:40: 50:50; 0:100), and sequentially with an 
EtOAc-MeOH gradient (100:0; 90:10; 85:15; 80:20; 75:25; 
70:30; 60:40; 50:50; 0:100). Based on the TLC profile, 
the fractions were assembled in 21 fractions (CP1-CP21). 
Fraction CP15 was purified on a silica column to obtain 
compound 1 (36.2 mg, 0.2 %). The compound detection 
was monitored at 254 nm. The purification of fraction CP19 
was performed using an HPLC Shimadzu, model SL6Vp 
equipped with an octadecilsilane-C18 (20 × 250 mm, 10 µm) 
preparative column. The eluent consisted of an isocratic 
ternary mixture of H2O:MeOH:MeCN (8:32:60). The 
samples were injected in a volume of 1 mL (20 mg mL-1) 
with a flow rate of 9 mL min-1, and the compound detection 
was monitored at 190, 209 and 254 nm. At the end of this 
process, four compounds were isolated, δ-tocotrienol (2, 
1.4 mg, 0.009 %), δ-tocotrienolic alcohol (3, 10.2 mg, 
0.07%), Z-δ-tocotrienoloic acid (4, 85.3 mg, 0.6%) and 
δ-tocotrienol-methyl ester (5, 0.6 mg, 0.004%). Betulinic 
acid (6, 100 mg, 0.7%) and β-sitosterol (7, 20.2 mg, 0.1%) 
were also isolated.
A methyl ether derivative (1a) of clusiaxanthone (1) was 
produced by methylation of 1 with diazomethane. Compound 
4a was obtained by the methylation of a hydroxyl and 
terminal carboxyl of Z-δ-tocotrienoloic acid (4).
1,7-Dihydroxy-2-(3-methyl-2-butenyl)-6’,6’-dimethyl-
pyrano(2’,3’:3,4)xanthone (1): yellow solid; [α]D -57.4 
(MeOH, c 0.11); IR ν/cm-1 3324, 2983, 2962, 2909, 
2857, 1700, 1647, 1480, 1465, 1357; 1H and 13C NMR 
(500.13 and 125.77 MHz, C5D5N, d/ppm) see Table 1; 
HRESIMS (positive mode) m/z found: 379.1540 [M + H]+; 
calc m/z for [C23H23O5]+ = 379.1545.
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1-Hydroxy,7-methoxy-2-(3-methyl-2-butenyl)-
6’,6’-dimethyl pyrano(2’,3’:3,4)xanthone (1a): yellow 
solid. 1H and 13C NMR (500.13 and 125.77 MHz, C5D5N, 
d/ppm) see Table 1. HRESIMS (positive mode) m/z found: 
393.1699 [M + H]+; calc m/z for [C24H25O5]+ = 393.1702.
Leishmania (Leishmania) amazonensis promastigote 
culture 
C57BL/6 mice were infected with Leishmania 
(Leishmania) amazonensis (strain L(L)a)-MHOM/BR/PH8) 
and maintained in the biotherium at the Faculty of Health 
Science/Medicine (University of Brasília, Brazil). Blood was 
collected by puncture of the hind paw of infected animals. 
The parasites were incubated in McNeal, Novy and Nicolle 
(NNN) culture medium pH 7.2 at 22 °C for seven days, and 
subsequently in Schneider’s medium supplemented with 
20% fetal bovine serum and 0.25% gentamicin pH 7.2 at 
22 °C.
Compound evaluation in L. (L.) amazonensis promastigotes
Sterile Schneider’s medium (Sigma-Aldrich) was 
added to each well of a 96 well cell culture plate. 
Promastigotes (105) were then added to the wells and 
counted in a Neubauer chamber. Serial dilution of 
the compounds was performed starting at an initial 
concentration of 300 mmol L-1, with 0.1% DMSO 
(dimethyl sulfoxide) as a negative control. The cell culture 
plate was incubated for 48 h at 22-26 °C. Next, 100 µg per 
well of a solution of 5 mg mL-1 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) in PBS 
(phosphate buffered saline, Sigma-Aldrich) was added 
to the wells for 4 h at 37 °C. Viability measurements 
were performed after the addition of 100 mL DMSO to 
solubilize the formazan crystals.40-42 In this experiment, 
we used promastigotes in log phase growth to optimize the 
spectrophotometer reading at 570 nm. The experiments 
were performed in triplicate, and the IC50 values were 
calculated using Microsoft Excel®.
Compound evaluation in L. (L.) amazonensis amastigotes
Peritoneal macrophages from BALB/c mice were 
collected and centrifuged in RPMI 1640 (Gibco) medium 
at 1190 rpm or 300 g. The pellets were recovered and 
resuspended to count the viable cells by trypan blue 
(Sigma) staining in a Neubauer chamber. Glass coverslips 
(13 mm) were placed into a 24 well plate with 4 × 105 
macrophages per well for 24 h at 37 °C in a 5% CO2 
atmosphere. After the incubation period, the non-adherent 
cells were removed and the macrophages were incubated 
with L. (L.) amazonensis promastigotes in stationary 
phase at a ratio of 10:1 for 4 h at 37 °C in a 5% CO2 
atmosphere. The promastigote-free supernatant was 
removed, and the infected macrophages were treated with 
the compounds at initial concentrations of 300 µmol L-1 
for 48 h. The cells were subsequently harvested, fixed 
with methanol and stained with Giemsa stain. Miltefosine 
(Sigma-Aldrich), amphotericin B (Sigma-Aldrich), and 
meglumine antimoniate (Glucantime®, Aventis Pharma 
Brazil; 300 mg mL-1, 81 mg mL-1 Sb (V)) at concentrations 
of 30.0 to 0.056 µmol L-1 were used as positive controls, and 
0.1% DMSO in a culture medium with amastigotes as a 
negative control. For each concentration of compound, 
200 macrophages were counted using an optical microscope 
(Olympus). The number of amastigote-infected cells was 
calculated compared to the negative control.43,44 The tests 
were performed in triplicate.
Evaluation of compound cytotoxicity in murine macrophages
After the peritoneal macrophages were isolated from 
BALB/c mice, 106 cells were placed in each well of a 
96 well microplate. The cells were incubated for 12 h at 
37 °C in a 5% CO2 atmosphere. The culture medium was 
then replaced with the diluted compounds in new culture 
medium, and the cells were then incubated at 37 °C in a 5% 
CO2 atmosphere. A solution of 0.1% DMSO was used as the 
negative control. After 24 h, cell viability was determined 
by adding 100 µg per well MTT in PBS (5 mg mL-1) for 4 h. 
The culture medium was removed and 100 µL DMSO was 
added. The formazan was quantified in a spectrophotometer 
at 570 nm.45,46
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Figure S1. 1H NMR spectrum (500 MHz, C5D5N) of clusiaxanthone (1).
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Figure S3. 13C DEPT 135 NMR spectrum (125 MHz, C5D5N) of clusiaxanthone (1).
Figure S2. 13C NMR spectrum (125 MHz, C5D5N) of clusiaxanthone (1).
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Figure S5. HMBC spectrum (C5D5N) of clusiaxanthone (1).
Figure S4. HSQC spectrum (C5D5N) of clusiaxanthone (1).
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Figure S7. HRESIMS spectrum of clusiaxanthone (1) in the positive mode [M + H]+.
Figure S6. COSY spectrum (C5D5N) of clusiaxanthone (1).
Silva et al. S5Vol. 24, No. 8, 2013
Figure S9. 13C NMR spectrum (125 MHz, CDCl3 + CD3OD) of the derivative 1a, obtained from clusiaxanthone (1).
Figure S8. 1H NMR spectrum (500 MHz, CDCl3 + CD3OD) of the derivative 1a, obtained from clusiaxanthone (1).
Clusiaxanthone and Tocotrienol Series from Clusia pernambucensis and their Antileishmanial Activity J. Braz. Chem. Soc.S6
Figure S11. HMBC spectrum (CDCl3 + CD3OD) of the derivative 1a, obtained from clusiaxanthone (1).
Figure S10. HSQC spectrum (CDCl3 + CD3OD) of the derivative 1a, obtained from clusiaxanthone (1).
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Figure S12. HRESIMS spectrum of the derivative 1a, obtained from clusiaxanthone (1) in the positive mode [M + H]+.
